East cancer, pancreatic cancer Monotherapy in individuals with deleterious

(Daetwyler et al. 2007). {Therefore|Consequently|As a result|For that reason Nucleic Acids Res. 2006;34(Database concern):D668 672, by permission of Oxford University Press.78 Abbreviations: FDa, Meals and Drug administration; her2, human epidermal development element receptor two; nsclc, non-small-cell lung cancer; egFr, epidermal growth element receptor; all, acute lymphoid leukemia; gisT, gastrointestinal stromal tumor; cMl, chronic myeloid leukemia; rcc, renal cell carcinoma; alK, anaplastic lymphoma kinase.OncoTargets and Therapy 2017:submit your manuscript | www.dovepress.comDovepresschaiyawat et alDovepressTable six Up-regulated proteins and genes which can be targets of FDa-approved non-antineoplastic drugsGene ATP1A1 ATP1B1 DHODH Protein name na+/K+-aTPase Dihydroorotate dehydrogenase (quinone), mitochondrial FDA-approved drug Digoxin Digitoxin Leflunomide Drug category antiarrhythmia agent immunosuppressive agent Disease indicationa For the remedy and management of congestive cardiac insufficiency, arrhythmias, and heart failure. For the management of the signs and symptoms of active ra. has also been applied for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDa as an orphan drug for this use. For the prophylaxis of organ rejection in individuals receiving allogeneic renal, cardiac, or hepatic transplants.East cancer, pancreatic cancer Monotherapy in patients with deleterious or suspected deleterious germline Brca mutated (as detected by an FDa-approved test) sophisticated ovarian cancer that have been treated with 3 or more prior lines of chemotherapy ALL, GIST, dermatofibrosarcoma protuberans, CML, myelodysplastic syndrome, systemic mastocytosis advance renal cell carcinoma, some hepatocellular carcinoma Metastatic renal cell carcinoma, gisT (no response to imatinib), pancreatic neuroendocrine tumor advanced renal cell carcinoma, sophisticated soft tissue sarcoma cMl sophisticated renal cell carcinoma all, cMl Several myeloma, mantle cell lymphoma A number of myelomaado-trastuzumab emtansine (KaDcYla)afatinib (gilOTriF)Pertuzumab (PerJeTa)GSR HDAC1 HDAC2 KITglutathione reductase, mitochondrial histone deacetylase 1 histone deacetylase 2 Mast/stem cell development issue receptor kitcarmustine (gliaDelWaFer) Vorinostat (Zolinza) romidepsin (istodax) imatinib mesylate (gleevec) sorafenib (nexavar) sunitinib (sutent) Pazopanib (Votrient) Dasatinib (sprycel) axitinib (inlyta) nilotinib (Tasigna) lenvatinib (lenvima) cabozantinib (cOMeTriQ) crizotinib (XalKOri)FGFR1 METFibroblast growth aspect receptor 1 hepatocyte growth element receptorMTORserine/threonine protein kinase mTOr Poly (aDP-ribose) polymeraseTemsirolimus (Torisel) Everolimus (Afinitor) Olaparib (aZD2281)PARPPDGFRPlatelet-derived development issue receptor alphaimatinib mesylate (gleevac) sorafenib (nexavar) sunitinib (sutent) Pazopanib (Votrient) nilotinib (Tasigna) axitinib (inlyta) Dasatinib (sprycel) Bortezomib (Velcade) Carfilzomib (Kyprolis)PSMC2 PSMC5 PSMC26s protease regulatory subunit 7 26s protease regulatory subunit 8 26s protease regulatory subunit 10BNote: ainformation from Termglinchan et al and DrugBank Version four.five. republished with permission of Dovepress, from Onco Targets Ther, candidate cancer-targeting agents identified by expression-profiling arrays, Termglinchan V, Wanichnopparat W, Suwanwongse K, et al, 6, copyright 2013; permission conveyed by means of Copyright Clearance center, inc.77 Wishart Ds, Knox c, guo ac, et al. DrugBank: a complete resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database concern):D668 672, by permission of Oxford University Press.78 Abbreviations: FDa, Food and Drug administration; her2, human epidermal growth factor receptor 2; nsclc, non-small-cell lung cancer; egFr, epidermal growth issue receptor; all, acute lymphoid leukemia; gisT, gastrointestinal stromal tumor; cMl, chronic myeloid leukemia; rcc, renal cell carcinoma; alK, anaplastic lymphoma kinase.OncoTargets and Therapy 2017:submit your manuscript | www.dovepress.comDovepresschaiyawat et alDovepressTable six Up-regulated proteins and genes that happen to be targets of FDa-approved non-antineoplastic drugsGene ATP1A1 ATP1B1 DHODH Protein name na+/K+-aTPase Dihydroorotate dehydrogenase (quinone), mitochondrial FDA-approved drug Digoxin Digitoxin Leflunomide Drug category antiarrhythmia agent immunosuppressive agent Illness indicationa For the remedy and management of congestive cardiac insufficiency, arrhythmias, and heart failure. For the management with the signs and symptoms of active ra.